Telix Pharmaceuticals Reports Q1 2026 Revenue Growth and Advances Therapeutics Pipeline

Telix Pharmaceuticals reported strong Q1 2026 financial results with unaudited group revenue of US$230 million, representing an 11% increase quarter-over-quarter and 24% year-over-year. The growth was primarily driven by the Precision Medicine segment, which saw US$186 million in revenue, up 16% from the previous quarter, bolstered by the performance of Illuccix and Gozellix. The company reaffirmed its FY 2026 revenue guidance of US$950 million to US$970 million and R&D expenditure guidance of US$200 million to US$240 million. Clinically, Telix achieved significant milestones: the Phase 3 ProstACT Global trial for TLX591-Tx met its safety and dosimetry objectives in Part 1. The company resubmitted the NDA for brain cancer imaging candidate TLX101-Px (Pixclara) to the FDA and filed an MAA in Europe. Additionally, Telix is preparing for a H1 2026 BLA resubmission for Zircaix (TLX250-Px) following successful FDA meetings. Corporate updates include the appointment of David Gill as Non-Executive Director, effective May 11, 2026, with plans for him to eventually succeed Dr. Mark Nelson as Chair.